Barclays
SGNT

Barclays’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Barclays’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-456
Closed -$7K – 7034
2016
Q2 		$7K Sell
456
-2,100
-82% -$27K ﹤0.01% 5679
2016
Q1 		$31K Buy
2,556
+2,041
+396% +$28.6K ﹤0.01% 5042
2015
Q4 		$8K Sell
515
-8,802
-94% -$139K ﹤0.01% 5476
2015
Q3 		$140K Buy
9,317
+8,863
+1,952% +$192K ﹤0.01% 4393
2015
Q2 		$11K Sell
454
-626
-58% -$15K ﹤0.01% 6061
2015
Q1 		$25K Sell
1,080
-2,997
-74% -$79.3K ﹤0.01% 5722
2014
Q4 		$102K Sell
4,077
-4,279
-51% -$126K ﹤0.01% 5195
2014
Q3 		$258K Sell
8,356
-479
-5% -$13K ﹤0.01% 4513
2014
Q2 		$221K Buy
8,835
+2,774
+46% +$61.6K ﹤0.01% 4724
2014
Q1 		$140K Buy
6,061
+4,824
+390% +$106K ﹤0.01% 5136
2013
Q4 		$31K Sell
1,237
-4,082
-77% -$92.2K ﹤0.01% 6482
2013
Q3 		$106K Buy
5,319
+4,451
+513% +$99.1K ﹤0.01% 5568
2013
Q2 		$18K Buy
+868
New +$15.5K ﹤0.01% 6897

Barclays's SGNT Position: Q3 2016 in Review

Barclays sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 456 shares — an estimated $7K sold.

Barclays first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $258K in Q3 2014. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.

  • Barclays reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
  • Barclays sold 456 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $7K.
  • Barclays first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
  • Barclays's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $258K in Q3 2014.
  • 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.

Based on Barclays's 13F filing for Q3 2016, filed 14 Nov 2016.